Biota Holdings Limited
News
iSOFT Group Limited (ASX:ISF), Australia's largest listed health information technology company today announced the appointment of Dr. James (Jim) Fox as Deputy Chairman. This decision affirms the Board's commitment to the continual process of review and development of the Company's overall corporate governance position and the composition of the Board.
US stocks surged overnight as the Federal Reserve said the economy was leveling out, and it left interest rates unchanged at the end of its two-day policy meeting.
iSOFT Group Limited (ASX:ISF) Australia's largest listed health information technology company today announced the appointment of Dr. James (Jim) Fox as Non-Executive Director, as iSOFT seeks to increase the number of independent directors on its Board.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) notes that GlaxoSmithKline (GSK) has announced important initiatives to assist governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain (previously referred to as Swine Flu).
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received notification from GlaxoSmithKline (LON:GSK) that Relenza sales were A$462 million and indicative royalties were A$32.3 million, for the three months ended 31 March 2009.
The Australian share closed slightly higher lifted by miners. The benchmark S&P/ASX200 index ended the day up 0.7%, or 25.7 points, at 3672.3, while the broader All Ordinaries index rose 0.8%, or 29.3 points, at 3615.6. For the week, the ASX200 added 6% and the All Ordinaries rose 6.2%.
Biota Holdings Limited (ASX:BTA) Daiichi-Sankyo (TYO:4568) Exercise Right To Market CS-8958 In Japan
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that Daiichi Sankyo (TYO:4568), the co-owner of the long acting neuraminidase inhibitor (LANI) CS-8958, has signed a contract to manufacture and market the product in Japan, pending the successful completion of the pivotal Phase III clinical studies and on obtaining registration approval. Biota, as one of the owners, will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones in the Japanese market.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) announced today the appointment of Dr James Fox as a non executive Director and Chairman, effective 27 February 2008.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported NPAT of A$7.2 million for the first half ended December 2008, up 31 percent from the previous corresponding period. Excluding the A$20 million GlaxoSmithKline (GSK) litigation settlement, the underlying business booked a net loss of A$12.8 million for the half versus net profit of A$5.5 million previously.
Biota Holdings Limited (ASX: BTA)(PINK:BTAHY) today announced a half year net profit after tax of A$7.2 million, (1H F08: A$5.5 million), a 31% improvement over first half F08. Profit before tax was A$10.1 million (1H F08: A$7.5 million) and includes A$12.7 million from the GSK litigation settlement in the period.
121,357 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 50) (Last 30 Days: 331) (Since Published: 27153)